2018
-
Barriers to Access to New Lung Cancer Drugs in Latin America
By Pedro N. Aguiar Jr., MD, MSc, andGilberto L. Lopes Jr., MD, MBA Posted: April 2018 After often-painful but effective and still incomplete economic reforms, more rational government spending, and […]
-
Q&A with the New IASLC President
Posted: February 2018 Giorgio Vittorio Scagliotti, MD, Professor of Oncology at University of Torino and Head of the Department of Oncology and Chief of the Division of Medical Oncology at […]
-
Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC
By Hossein Borghaei, MS, DO Posted: February 2018 The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For patients who are treatment […]
-
Laurie E. Gaspar, MD, MBA
Posted: February 2018 Laurie E. Gaspar, MD, MBA, has been elected as the 2019- 2020 Treasurer of ASCO. Dr. Gaspar is Professor Emeritus in the Department of Radiation Oncology at […]
-
Radon: A Modifiable Lung Cancer Risk Factor
By Douglas Arenberg, MD Posted: February 2018 There has been rapid change over the past decade in the field of lung cancer. Advances such as histology-specific treatments, targeted agents, immunotherapy, […]
-
European Union Position Statement on Lung Cancer CT Screening: The Next 18 Months
By John K. Field, PhD, and Matthijs Oudkerk, MD, PhD Lung cancer kills more Europeans than any other cancer. In 2014, 272,000 citizens of the twenty-eight countries in the European […]
-
The Upcoming Lung Cancer Neoadjuvant Meeting
(Photo: Gideon Blumenthal, MD, Nicole Drezner, MD, Mark G. Kris, MD) By Erik J. MacLaren, PhD Posted: February 2018 The development of immunotherapies and targeted therapies for use in lung cancers […]
-
Paolo Paoletti, MD
New IASLC Foundation Board Member Posted: February 2018 Dr. Paoletti is the Chairman of the Board for Genmab, PsiOxus Therapeutics (Chairman of the Board), FORMA Therapeutics, and Nucana Biomed. He […]
-
Targeted Therapies Meeting Focuses on Upcoming Research Advances in Lung Cancer
By Chairs Suresh Ramalingam, MD, Paul Bunn, MD, PhD, Leora Horn, MD, MSc, and Roy Herbst, MD, PhD Posted: February 2018 Lung cancer research has reached an exciting point with […]
-
Howard A. “Skip” Burris III, MD
Posted: February 2018 Howard A. “Skip” Burris III, MD, has been elected to serve as the 2019-2020 President of the American Society of Clinical Oncology (ASCO) for the term beginning […]
View ILCN Archives
Provider Resources